CHRONOS
We are conducting the qualitative element and longitudinal interviews with patients and clinicians participating in the CHRONOS trial.
Background
This trial is comparing treatment to the whole prostate with treatment to only the areas of cancer in the prostate.
Patients can be assigned to one of two parts of the CHRONOS trial - CHRONOS A or CHRONOS B. They are then randomised to receive a particular therapy.
| CHRONOS A | Focal therapy alone (High-Intensity Focussed Ultrasound (HIFU) or Cryotherapy) - or radical therapy (removal of the prostate through surgery, radiotherapy or brachytherapy). |
|---|---|
| CHRONOS B | Focal therapy alone or focal therapy in combination with neoadjuvant and/or adjuvant agents i.e. hormone treatment (Finasteride or Bicalutamide). |
Patients who participate or decline participation in the trial will be invited to take part in qualitative interviews.
Aim
To explore the patients’ experiences of treatments including side-effects and their quality of life, also patients and clinicians’ perspectives of recruitment to the trial.
Impact
The results from qualitative interviews are fed back to the main trial in real-time.
Taking part
You may be able to join this sub-study if you are eligible for the CHRONOS trial.
Who can’t take part
You cannot take part in the study if you have already had treatment for prostate cancer.
The study is sponsored by Imperial College London.
Information
| Chief Investigator | Professor Hashim U Ahmed |
|---|---|
| Qualitative Lead | Professor Annmarie Nelson |
| Qualitative Study contact | Dr Mirella Longo |
| Funder | Prostate Cancer UK |
| Start date | 11 December 2019 |
| End date | 30 September 2021 |
| Status | CHRONOS A and the qualitative component are open |
